Literature DB >> 19075721

Intermittent and long-term use of sedative hypnotics.

Michael Perlis1, Philip Gehrman, Dieter Riemann.   

Abstract

In this review, the context and evidence base for intermittent and long term dosing with hypnotics is critically evaluated. The context provided includes addressing two questions: "why has long term or maintenance therapy not been a standard for practice for the treatment of chronic insomnia?"; and "why is intermittent dosing thought to represent a potential solution for the problem of chronic insomnia?". The data from the systematic review suggests, over all, that: 1) while intermittent dosing can be conducted without resulting in rebound insomnia on non-med nights, there is insufficient data to show that the strategy is equal, or superior, to nightly dosing on a long term basis; 2) long term therapy (up to 6 months) with intermittent or nightly dosing appears viable to the extent that clinical outcomes are stable over time and occur in the absence of dose escalation or increased adverse events. The discussion section of the review includes: an analysis of the future prospects for intermittent dosing (with or without placebos); the suggestion that the use of placebos in an intermittent dosing regimen presages the use of partial reinforcement principles to enhance the safety and efficacy of the approach; finally the discussion contains a challenge to re-think, from first principles, whether the underlying approach to the medical management of insomnia is rational. It is suggested that a more rational approach is possible and that medical therapy for insomnia needs to be re-assessed for it's curative (vs palliative) potential.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19075721     DOI: 10.2174/138161208786549290

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  5 in total

1.  A pilot study of audio-visual stimulation as a self-care treatment for insomnia in adults with insomnia and chronic pain.

Authors:  Hsin-Yi Tang; Michael V Vitiello; Michael Perlis; Jun James Mao; Barbara Riegel
Journal:  Appl Psychophysiol Biofeedback       Date:  2014-12

2.  Durability of treatment response to zolpidem with three different maintenance regimens: a preliminary study.

Authors:  Michael Perlis; Michael Grandner; Jarcy Zee; Erin Bremer; Julia Whinnery; Holly Barilla; Priscilla Andalia; Phil Gehrman; Knashawn Morales; Michael Thase; Richard Bootzin; Robert Ader
Journal:  Sleep Med       Date:  2015-07-07       Impact factor: 3.492

3.  Why treat insomnia?

Authors:  Sara E Matteson-Rusby; Wilfred R Pigeon; Philip Gehrman; Michael L Perlis
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

Review 4.  Insomnia in the Older Adult.

Authors:  Glenna S Brewster; Barbara Riegel; Philip R Gehrman
Journal:  Sleep Med Clin       Date:  2017-11-22

5.  Durability of treatment response to zolpidem using a partial reinforcement regimen: does this strategy require priming?

Authors:  Michael L Perlis; Knashawn H Morales; Ivan Vargas; Alexandria Muench; Mark Seewald; Nalaka Gooneratne; Michael A Grandner; Michael E Thase; Ted J Kaptchuk; Robert Ader
Journal:  Sleep Med       Date:  2021-08-21       Impact factor: 4.842

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.